Recent News

Relapsed AML in Children and Hematopoietic Cell Transplantation

Predicting Low-Risk Febrile Neutropenia in Chemotherapy-Treated Patients With AML

Suicide Risk Factors for Patients With AML and Other Leukemias

Anti–TIM-3 Monoclonal Antibody Under Study in AML

Rare Occurrence of Secondary CML After AML: Case Study

Novel Treatment Under Study in Transplantation-Eligible Patients With AML

Early Results With Eftozanermin Alfa Plus Venetoclax in AML

How Does Minimal Residual Disease Impact Clinical Outcomes in Acute Leukemias?

Venetoclax Combination Therapy for Acute Myeloid Leukemia Approved by FDA

Potential of IDH1 Inhibitors in AML Prior to Hematopoietic Cell Transplantation

SIERRA Trial Update on Novel Conditioning Regimen for Older Patients With AML

Pediatric AML: Combination Therapy With Venetoclax and Azacitidine

SOHO 2020: GI Side Effects for Patients With AML Treated With CC-486

SOHO 2020: Survival Update From BRIGHT Trial of Glasdegib-Based Therapy for AML

Long-Term Psychosocial and Neurocognitive Impact of Childhood AML

SOHO 2020: Elevated LDH Levels and Overall Survival in AML

Clinical Implications of Condensing HDAC Regimen in Treatment of AML

NPM1‐Mutant AML and COVID-19: Modified Protocols for Monitoring Treatment Response

Stem Cell Transplantation and AML: WT1 Expression and Outcomes

Azacitidine Tablets Approved by FDA for Patients With AML in First Remission

Selinexor in Refractory Oligoblastic AML: Phase II Trial Findings

AML and COVID-19: Treatment Lessons Learned

Glasdegib After Transplantation in Patients With AML at High Risk for Relapse

Does Treatment Delay Affect Outcomes in AML?

Personalized Immunotherapy for Resistant AML

Antimetabolite Aspacytarabine Receives Fast Track Designation for AML Treatment

New ASH Guidelines Focus on Managing AML in Older Adults

Use of Anthracyclines and Stem Cell Transplantation in AML: Outcomes by Age

Primary Antifungal Prophylaxis in Patients Treated for Acute Myeloid Leukemia

Factors Predictive of Response to Venetoclax Treatment in AML

Third-Generation BCR-ABL Inhibitor Under Study in AML

AACR COVID: Clinical Experience in Treating Pediatric Patients With AML and Coronavirus

Pexidartinib for Relapsed or Refractory FLT3-ITD–Mutant AML

EHA25: Ponatinib Plus Azacitidine for FLT3-Mutated AML

Occupational Exposure to Pesticides and AML Risk

EHA25: Early Results With Alvocidib Followed by Chemotherapy for Newly Diagnosed AML

EHA25 Virtual: 6-Month VIALE-C Update on Venetoclax With Low-Dose Cytarabine in AML

Early Blood Cell Counts and Survival After Treatment of Newly Diagnosed AML

EHA25 Virtual: 5-Year Follow-up on Novel Dual-Drug Formulation in AML

Using Patient-Reported Data to Predict Survival in AML

EHA25 Virtual: FLT3 Inhibitor Plus Chemotherapy for Younger Patients With AML

ASCO20: 1-Year ADMIRAL Trial Update on Gilteritinib in Resistant AML

AACR II: Race-Based Survival Differences in Patients With AML Living in Texas

EHA25 Virtual: Venetoclax Plus Low-Dose Cytarabine for Older Adults With AML

First-in-Class Immunotherapy With Azacitidine Under Study in AML

FDA Approves Gemtuzumab Ozogamicin for Pediatric CD33-Positive AML

EHA25 Virtual: Azacitidine Versus Fludarabine Plus Cytarabine in Elderly Patients With AML

EHA25 Virtual: Venetoclax Plus Azacitidine in Older Patients With AML Who Are Ineligible for Intensive Therapy

ASCO20: Ivosidenib and Venetoclax in Treatment of IDH1-Mutated AML

ASCO20: Escalated Dosing Schedule of CC-486 in Patients With AML in First Relapse

ASCO20: Enasidenib Plus Azacitidine in Newly Diagnosed Mutant-IDH2 AML

ASCO20: Is Palliative Care of Benefit in Patients With High-Risk AML?

ASCO20: Adding Venetoclax to Cytarabine in Older Patients With AML